
Entelexo Biotherapeutics
Entelexo Biotherapeutics is a YC Winter 2021 (W21) company. Based in Irvine, CA, USA. Team of 3.
About Entelexo Biotherapeutics
Summary
Entelexo Biotherapeutics develops engineered exosome-based therapeutics for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. Its platform engineers exosomes to deliver signals to multiple specific cell types simultaneously, targeting several disease pathways at once. This contrasts with existing single-cytokine-blocking drugs, which treat all patients identically and leave the underlying disease complexity unaddressed.
From the Y Combinator listing
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
Entelexo is creating modern treatments for immune-mediated diseases, such as psoriasis, using novel engineered exosome technology.
Facts
- Healthcare / Healthcare -> Therapeutics
- Irvine, CA, USA
- 3
- Active
- Early
Founders (3)
- Cameron Taylor
- MILAD RIAZIFAR
- Todd Schurr
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works